Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Gw Pharma ADR (GWPH)

Gw Pharma ADR (GWPH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,110,289
  • Shares Outstanding, K 31,047
  • Annual Sales, $ 311,330 K
  • Annual Income, $ -9,020 K
  • 60-Month Beta 1.78
  • Price/Sales 10.17
  • Price/Cash Flow N/A
  • Price/Book 4.42

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.63
  • Number of Estimates 11
  • High Estimate -0.24
  • Low Estimate -1.05
  • Prior Year -0.48
  • Growth Rate Est. (year over year) -31.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
95.12 +5.32%
on 09/08/20
111.23 -9.93%
on 09/15/20
-6.89 (-6.44%)
since 08/18/20
3-Month
95.12 +5.32%
on 09/08/20
141.98 -29.44%
on 07/15/20
-31.00 (-23.63%)
since 06/18/20
52-Week
67.98 +47.37%
on 03/17/20
141.98 -29.44%
on 07/15/20
-35.54 (-26.19%)
since 09/18/19

Most Recent Stories

More News
Cannabis Beverages Market Size to Reach USD 8,521.6 Million by 2027; Possession of Functional Benefits to Propel Growth, Says Fortune Business Insights(TM)

The global cannabis beverages market size is set to gain impetus from the increasing popularity of these products owing to their possession of several functional benefits, such as easy availability, ease...

APHA : 4.68 (+0.43%)
GWPH : 100.18 (-1.79%)
MEDFF : 18.8100 (-0.37%)
OGI : 1.1400 (+0.88%)
Rising Demand for Wellness Drinks to Foster the Growth of Cannabis Beverages Market

Research Nester published a report titled which delivers a detailed overview of the cannabis beverage market in terms of market segmentation by type, by constituent, by distribution channel, by application,...

ACB.TO : 8.62 (-4.86%)
MEDFF : 18.8100 (-0.37%)
WEED.TO : 21.57 (-0.05%)
APHA : 4.68 (+0.43%)
CRON : 5.29 (+0.95%)
GWPH : 100.18 (-1.79%)
CNTTQ : 0.2980 (+1.02%)
VIVO : 16.65 (+6.80%)
TLRY : 5.34 (-1.66%)
OGI : 1.1400 (+0.88%)
ACB : 6.53 (-5.22%)
GW Pharmaceuticals Announces the Appointment of David Gryska to its Board of Directors

GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines today announced the appointment of David Gryska to the Board...

GWPH : 100.18 (-1.79%)
Legislative Breakthroughs Propel the Medical Cannabis Industry Forward

, /PRNewswire/ --  Cannabis is continuously growing as a popular option for medical treatments due to its beneficial and diverse treatment options. In fact, multiple countries have adopted regulatory...

ACB.TO : 8.62 (-4.86%)
MEDIF : 0.6755 (-2.55%)
LABS.TO : 0.89 (-1.11%)
AVCN.TO : 1.20 (+9.09%)
AVCNF : 0.9000 (+5.88%)
TLRY : 5.34 (-1.66%)
CGC : 16.36 (-0.24%)
ACB : 6.53 (-5.22%)
GWPH : 100.18 (-1.79%)
60 Minutes: Psychedelics Could Help People with Addiction and Anxiety

Psychedelic drug treatments are quickly going mainstream, with new coverage surfacing from 60 Minutes. ...

GWPH : 100.18 (-1.79%)
RVVTF : 0.1945 (-2.75%)
MMEDF : 0.3920 (+15.81%)
JNJ : 149.18 (+1.37%)
NUMI.VN : 0.240 (+6.67%)
RVV.CN : 0.255 (-3.77%)
This Landmark Decision is a Major Game Changer for Companies Focused on Psylocybin

The psychedelics boom is alive and well thanks in part to a landmark decision on psilocybin mushrooms. ...

RVVTF : 0.1945 (-2.75%)
MMEDF : 0.3920 (+15.81%)
JNJ : 149.18 (+1.37%)
NUMI.VN : 0.240 (+6.67%)
GWPH : 100.18 (-1.79%)
RVV.CN : 0.255 (-3.77%)
Cannabis Stock Weekly Recap

The cannabis industry was down for the week due to mixed news. Innovative Industrial Properties (IIPR) posted strong earnings, Aurora Cannabis (ACB) was trending downward, and GW Pharmaceuticals (GWPH)...

TCNNF : 19.1409 (-1.69%)
IIPR : 124.79 (-1.10%)
MJ : 11.18 (-0.97%)
ACB : 6.53 (-5.22%)
GWPH : 100.18 (-1.79%)
What's in Store for Meridian Bioscience's (VIVO) Q3 Earnings?

Meridian Bioscience's (VIVO) fiscal third-quarter results are likely to reflect strong performance by Life Science business line.

IART : 46.62 (+0.15%)
VIVO : 16.65 (+6.80%)
GWPH : 100.18 (-1.79%)
LVGO : 132.37 (+3.43%)
GW Pharma Paves the Way to More Revenue

The FDA just approved GW Pharmaceuticals (GWPH) Epidiolex Oral Solution to treat seizures associated with Tuberous Sclerosis Complex. This is the third approval for the drug. On Monday, GW Pharmaceuticals...

GWPH : 100.18 (-1.79%)
ABIOMED (ABMD) to Report Q1 Earnings: What's in the Offing?

The commercial rollout of ABIOMED's (ABMD) Impella 5.5 is expected to have progressed steadily through the fiscal first quarter.

IART : 46.62 (+0.15%)
ABMD : 265.07 (-4.01%)
GWPH : 100.18 (-1.79%)
NVRO : 142.50 (-1.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Trade GWPH with:

Business Summary

GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company's lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and...

See More

Key Turning Points

2nd Resistance Point 103.83
1st Resistance Point 102.01
Last Price 100.18
1st Support Level 98.50
2nd Support Level 96.82

See More

52-Week High 141.98
Fibonacci 61.8% 113.71
Fibonacci 50% 104.98
Last Price 100.18
Fibonacci 38.2% 96.25
52-Week Low 67.98

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar